AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
Fuels Ambition To Be Leading Heart Failure Firm
Executive Summary
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
You may also be interested in...
Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties
AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications.
Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.